PET imaging in the management of tumors of testis and ovary: Current thinking and future directions

Minerva Endocrinologica

Volumn 33, Issue 3, 2008, Pages 229-256

  Basu, S ^a   Rubello, D ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Neoplasms; Ovary; Positron emission tomography; Prognosis; Testis; Treatment outcome

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CHORIONIC GONADOTROPIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; LACTATE DEHYDROGENASE; MELANOMA ANTIGEN 2; METHIONINE C 11; TUMOR MARKER; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANDROGEN INSENSITIVITY SYNDROME; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHORIOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CRYPTORCHISM; CYSTADENOMA; DIAGNOSTIC VALUE; ECHOGRAPHY; ENDOMETRIUM TUMOR; FIBROSIS; FOLLOW UP; GERM CELL TUMOR; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE DISSECTION; MALIGNANT TRANSFORMATION; METASTASIS; MINIMAL RESIDUAL DISEASE; ORCHIECTOMY; OVARY CARCINOMA; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIMORDIAL GERM CELL; PROGNOSIS; REVIEW; SEMINOMA; SERTOLI CELL TUMOR; TESTIS CANCER; TESTIS SIZE; TESTIS TERATOMA; TREATMENT RESPONSE; YOLK SAC TUMOR; ADOLESCENT; ADULT; BLOOD; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FORECASTING; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY TUMOR; PARANEOPLASTIC NEUROPATHY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCINTISCANNING; TESTIS TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PARANEOPLASTIC CEREBELLAR DEGENERATION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS;

EID: 58149392636     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. McLeod DG, Weiss RB, Stablein DM. Staging relationships and outcome in early stage testicular cancer: a report from the testicular cancer inter group study. J Urol 1991;145:1178-83.
2. Ries LA, Eisner MP, Kosary CL. SEER Cancer Statistics Review, 1975-2001. National Cancer Institute, Bethesda, MD; 2004.
3. In: Abeloff MD, Armitage JO, Lichter AS, editors. Clinical Oncology. 2nd edition. New York: Churchill Livingstone; 2000. p. 1906-45.
4. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337:242-53.
5. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1491-518.
6. Donohue JP, Thornhill JA, Foster RS. Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 1993;71:326-35.
7. de Wit R, Stoter G, Kaye SB. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15:1837-43. (Pubitemid 27209512)
8. Bredael JJ, Vugrin D, Whitmore WF Jr. Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer 1982;50:548-51.
9. Coleman JM, Coleman RE, Turner AR. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin Oncol (R Coll Radiol) 1998;10:237-41.
10. Fernandez EB, Moul JW. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I non seminomatous germ cell tumors. Urology 1994;44:548-52.
11. Quek ML, Simma-Chiang V, Stein JP. Postchemotherapy residual masses in advanced seminoma: Current management and outcomes. Expert Rev Anticancer Ther 2005;5:869-74.
12. Rathmall AJ, Brand IR. Early detection of relapse after treatment for metastatic germ cell tumors of the testis: an exercise in medical audit. Clin oncol R COLL Radiol 1993;5:34-8.
13. Read G, Stenning SP, Cullen MH. Medical research council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10:1762-8.
14. Flechon A, Bompas E, Biron P. Management of postchemotherapy residual masses in advanced seminoma. J Urol 2002;168:1975-9.
15. Puc HS, Heelan R, Mazumdar M. Management of residual mass in advanced seminoma: Results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14:454-460, 1996 (Pubitemid 26051007)
16. Schultz SM, Einhorn LH, Conces DJ. Management of postchemothreapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol 1989;7:1497-503.
17. Kitajima K, Nakamoto Y, Senda M, Onishi Y, Okizuka H, Sugimura K. Normal uptake of 18F-FDG in the testis: an assessment by PET/CT. Ann Nucl Med 2007;21:405-10.
18. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000;83:863-9.
19. De Santis M, Bokemeyer C, Becherer A. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740-44. (Pubitemid 32844786)
20. Bokemeyer C, Kollmannsberger C, Oechsle K. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer 2002;86:506-11.
21. Lewis DA, Tann M, Kesler K, McCool A, Foster RS, Einhorn LH. Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. J Clin Oncol 2006;24:54-5.
22. Ganjoo KN, Chan RJ, Sharma M. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999;17:3457-60. (Pubitemid 29517915)
23. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034-9.
24. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000;83:863-9.
25. Sanchez D, Zudaire JJ, Fernandez JM, Lopez J, Arocena J, Sanz G et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int 2002;89:912-6.
26. Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002;89:549-56.
27. Tsatalpas P, Beuthien-Baumann B, Kropp J, Manseck A, Tiepolt C, Hakenberg OW et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 2002;68:157-63.
28. Johns Putra L, Lawrentschuk N, Ballok Z, Hannah A, Poon A, Tauro A et al. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology 2004;64:1202-7. Erratum in: Urology 2005;65:632.
29. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000;27:590-4.
30. Albers P, Bender H, Yilmaz H. PET in clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999;53:808-11.
31. Cremerius U, Wildberger JE, Borchers H. Does PET using FDG improve clinical staging of testicular cancer? Results in 50 patients. Urology 1999;54:900-4.
32. de Wit M, Brenner W, Hartmann M, Kotzerke J, Hellwig D, Lehmann J et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 2008 [Epub ahead of print].
33. Maszelin P, Lumbroso J, Theodore C, Foehrenbach H, Merlet P, Syrota A. Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications. Prog Urol 2000;10:1190-9.
34. Lassen U, Daugaard G, Eigtved A, Højgaard L, Damgaard K, Rørth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003;3:396-402. (Pubitemid 36692865)
35. Huddart RA, O'Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK, Vasey P et al. NCRI Testis Tumour Clinical Study Group. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 - the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007;25:3090-5.
36. Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD et al. Early prediction of treatment response to high dose salvage chemotherapy in patients with relapsed germ cell cancer using FDG PET. Br J Cancer 2002;86:506-11.
37. Basu S, Nair N. Unilateral testicular relapse of abdominal non-Hodgkin lymphoma detected by FDG-PET. Pediatr Radiol 2006;36:274-5.
38. Romics I, Fekete S, Bély M, Esik O, Szende B. A case of bilateral testicular lymphoma. Pathol Oncol Res 1999;5:152-4.
39. Game X, Houlgatte A, Fournier R, Duhamel P, Baranger B, Khoury S. [Dedifferentiation of mature teratomas secondary to testicular cancer: report of 2 cases]. Prog Urol 2001;11:73-6; discussion 76-7.
40. Wolf G, Aigner RM, Schwarz T, Krippl P, Samonigg H. Diagnosis of a contralateral second testicular carcinoma by F18-FDG PET. Onkologie 2003;26:155-7.
41. Nguyen BD. PET imaging of Sertoli cell tumor in androgen insensitivity syndrome. Clin Nucl Med 2003;28:743-5.
42. Dreessen J, Jeanjean AP, Sindic CJ. Paraneoplastic limbic encephalitis: diagnostic relevance of CSF analysis and total body PET scanning. Acta Neurol Belg 2004;104:57-63. (Pubitemid 39359710)
43. Nahhas WA. Ovarian cancer: current outlook on this deadly disease. Postgrad Med 1997;102:112-20.
44. Young RC, Fuks Z, Hoskins WJ. Cancer of the ovary. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th edition. Philadelphia, PA: J. B. Lippincott Co.
45. Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-118F]FDG). Gynecol Oncol 1993;51:197-204.
46. Yoshida Y, Kurokawa T, Kawahara K. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR 2004;182;227-33.
47. Schroder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of 18-F-flurorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma. Int J Gynecol Cancer 1999;9:117-22.
48. Römer W, Avril N, Dose J, Ziegler S, Kuhn W, Herz M et al. [Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose]Rofo 1997;166:62-8.
49. Zimny M, Schroder W, Wolters S, Cremerius U, Rath W, Büll U. [18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results]. Nuklearmedizin 1997;36:228-33.
50. Rieber A, Nüssle K, Stöhr I, Grab D, Fenchel S, Kreienberg R et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol 2001;177:123-9.
51. Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L et al. The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. Gynecol Oncol 2007;105:145-9.
52. Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography - a prospective study. Gynecol Oncol 2008;108:265-70.
53. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17-21. (Pubitemid 32634948)
54. Drieskens O, Stroobants S, Gysen M, Vandenbosch G, Mortelmans L, Vergote I. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 2003;55:130-4.
55. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma A systematic review and meta-analysis. Eur J Radiol 2008;29 [Epub ahead of print].
56. Murakami M, Miyamoto T, Iida T, Tsukada H, Watanabe M, Shida M et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006;(16 Suppl 1):99-107.
57. Kubik-Huch RA, Dörffler W, von Schulthess GK, Marincek B, Köchli OR, Seifert B et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761-7.
58. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001;176:1449-54.
59. Hauth EA, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 2005;56:263-8.
60. Jiménez-Bonilla J, Maldonado A, Morales S, Salud A, Zomeño M, Román J et al. Clinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum Levels. Clin Positron Imaging 2000;3:231-6.
61. Yen RF, Sun SS, Shen YY, Changlai SP, Kao A. Whole body positron emission tomography with 18F-fluoro2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001;21:3691-4.
62. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002;29:797-803.
63. Cho SM, Ha HK, Byun JY, Lee JM, Kim CJ, Nam-Koong SE et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol 2002;179:391-5.
64. Nanni C, Rubello D, Farsad M, De Iaco P, Sansovini M, Erba P et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005;31:792-7.
65. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103:271-6.
66. Chung HH, Rang WJ, Kim JW, Park NH, Song YS, Chung JK et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nud Med Mol Imaging 2007;34:480-6.
67. Mangili G, Picchio M, Sironi S, Viganò R, Rabaiotti E, Bornaghi D et al. Integrated PET/CT as a first-line restaging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 2007;34:658-66.
68. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 2007;105:17-22. (Pubitemid 46441448)
69. García-Velloso MJ, Jurado M, Ceamanos C, Aramendía JM, Garrastachu MP, López-García G et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging 2007;34:1396-405.
70. Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 2008;33:112-8.
71. Sheng XG, Zhang XL, Fu Z, Li HQ, Li QS, Ma ZF et al. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi 2007;42:460-3.
72. Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2008;108:160-5.
73. Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.J Comput Assist Tomogr 2007;31:868-75.
74. Yamamoto Y, Oguri H, Yamada R, Maeda N, Kohsaki S, Fukaya T. Preoperative evaluation of pelvic masses with combined (18)F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet 2008;17 [Epub ahead of print].
75. Nishiyama Y, Yamamoto Y, Kanenishi K, Ohno M, Hata T, Kushida Y et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging 2008;35:287-95.
76. M Zimny, W Siggelkow and W Schroder. 2-[Fluorine-18]-fluoro-2-deoxy-d- glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001;83:310-5.
77. Castellucci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 2007;28:589-95.
78. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53.
79. Kurosaki H, Oriuchi N, Okazaki A, Tamaki T, Uki A, Izuta M et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann Nucl Med 2006;20:171-4.
80. Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging 1999;2:63-70.
81. Marchand V, Graveleau J, Lanctin-Garcia C, Bourbouloux E, Bridji B, Resche I et al. A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET. Gynecol Oncol 2007;105:545-7.
82. Komoto D, Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Toyama Y et al. A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response. Ann Nucl Med 2006;20:157-60.
83. Lapela M, Leskinen-Kallio S, Varpula. M, Grénman S, Salmi T, Alanen K et al. Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med 1995;36:2196-200.